Study finds zoledronic acid improves bone density in boys with DMD
Zoledronic acid increased spine and hip bone density in boys with Duchenne muscular dystrophy, but fracture risk remained during follow-up.
News
-
-
DMD RNA imbalance may limit benefits of genetic therapy
Uneven dystrophin RNA production is common in DMD and may limit how much dystrophin current genetic therapies can restore in muscle.
-
Telerehabilitation is a useful and effective approach in DMD, study finds
Telerehabilitation can expand the delivery and use of physical rehabilitation services in DMD.
-
Study examines effect of sleep problems in early DMD
Early-stage DMD sleep problems are primarily behavioral and not yet physiologically impactful, according to a recently published study.
-
(Z)-Endoxifen receives Rare Pediatric Disease designation from FDA
(Z)-Endoxifen, a drug being developed by Atossa Therapeutics for DMD, recently received Rare Pediatric Disease Designation from the FDA.
-
New data indicates DYNE-251 boosts dystrophin and preserves function
A new treatment candidate for DMD increased dystrophin levels and improved movement while keeping lung function steady.
-
New findings indicate that DMD begins to effect muscle in utero
A better grasp of the molecular mechanisms underpinning DMD may accelerate therapeutic development.
-
Deramiocel trial yields positive results in patients with DMD
Findings from the HOPE-3 trial indicate that deramiocel may improve cardiac and skeletal muscle health in patients with DMD.
-
Obestatin alleviates symptoms and improves muscle health in DMD models
In mouse and human cell models of DMD, treatment with obestatin repaired muscle damage and improved cellular function.
-
Glucocorticoids found to improve thinking ability in a Duchenne mouse model
A steroid improved memory and brain cell connections in a mouse model of Duchenne muscular dystrophy (DMD).
